Immune Checkpoint Inhibitor–Associated Myocarditis
Conditions
Interventions
Corticosteroid treatment group:NA
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. Histopathological diagnosis of immune checkpoint inhibitor-related myocarditis or clinical suspicion of immune checkpoint inhibitor-related myocarditis based on European Society of Cardiology guidelines 2. Myocardial markers, electrocardiogram and echocardiography were examined before ICIS treatment 3.Corticosteroids were used after the diagnosis of immune checkpoint inhibitor-associated myocarditis
Exclusion criteria
Exclusion criteria: 1. Non-immune checkpoint inhibitor-related myocarditis 2.Myocardial markers, electrocardiogram, and echocardiography were not performed before immune checkpoint inhibitor therapy 3.No corticosteroids were used after the diagnosis of immune checkpoint inhibitor-associated myocarditis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The influencing factors of immune checkpoint inhibitor associated myocarditis and its impact on patient survival;cardiac markers; | — |
Countries
China
Contacts
Public ContactXuelei Ma
Division of Biotherapy, Cancer Center, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University, No. 37 GuoXue Alley, Chengdu 610041, China
Outcome results
None listed